RE:RE:RE:RE:RE:RE:Quarterly Stats and Totals ...MrMugsy wrote: Looking for that comment about the pipeline being full ... interested in what that might mean.
Saw this regarding what to expect in the new year regarding launches and new sales ...
"So, the launches that we have coming up in the first half of next year are Lenvima and Halaven in Colombia. Those products are pending approval right now. We have – we are in launch phase on those two products in a couple of other markets, including like Chile and Argentina. And in Canada, we have the launch of Trelstar and Nerlynx."
Then we still have the EXELON transfers to complete so we can get further into selling ...
"For Exelon, we are still working on executing the transfers with Novartis. We have started to file for MA transfers, but we haven’t had any MA transfer already. We expect the first to occur in the first half of 2022. But so far, the numbers that you are seeing are really the profit transfer that we are booking."
And then Amal talks to the pipeline being full ... certainly want to see lots of activity here ...
"The pipeline continues to be quite full. The team is quite busy across – if you look at our growth strategies, we have kind of outlined really three prongs due to the increase of our product portfolio. So, in terms of acquisitions, looking at products or portfolios or companies with existing sales and licensing of innovative assets and on the BGx side the development and in-licensing as well. So, across all three, the team is quite active and deal flow continues to be quite strong across the territory."
Very encouraging for growth !!!
Exackly and Canada should contribute much more soon. Next quarters should be interesting.